In their retrospective report on the association of osteonecrosis of the jaw in patients being treated with TNF-α inhibitors, Brijs and colleagues reviewed 2,701 patients with inflammatory bowel disease (IBD) and cross-matched them with patients who met the criteria for MRONJ. Here, TNF is linked to inflammatory bowel disease.